CN102432683B - 一种多表位tk1抗体的制备及其在肿瘤患者早期复发风险及预后评估中的应用 - Google Patents
一种多表位tk1抗体的制备及其在肿瘤患者早期复发风险及预后评估中的应用 Download PDFInfo
- Publication number
- CN102432683B CN102432683B CN 201110353972 CN201110353972A CN102432683B CN 102432683 B CN102432683 B CN 102432683B CN 201110353972 CN201110353972 CN 201110353972 CN 201110353972 A CN201110353972 A CN 201110353972A CN 102432683 B CN102432683 B CN 102432683B
- Authority
- CN
- China
- Prior art keywords
- antibody
- human
- peptide
- peptides
- igy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100034838 Thymidine kinase, cytosolic Human genes 0.000 title claims abstract description 111
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 55
- 238000004393 prognosis Methods 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 24
- 238000011156 evaluation Methods 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 82
- 238000001514 detection method Methods 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 44
- 230000036039 immunity Effects 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 28
- 238000004043 dyeing Methods 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 16
- 238000007639 printing Methods 0.000 claims description 14
- 210000002969 egg yolk Anatomy 0.000 claims description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000011091 antibody purification Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 4
- 229920001220 nitrocellulos Polymers 0.000 claims description 4
- 208000019065 cervical carcinoma Diseases 0.000 claims description 3
- 229960001438 immunostimulant agent Drugs 0.000 claims description 3
- 239000003022 immunostimulating agent Substances 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000002038 chemiluminescence detection Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 33
- 102000036639 antigens Human genes 0.000 abstract description 33
- 108091007433 antigens Proteins 0.000 abstract description 33
- 230000035945 sensitivity Effects 0.000 abstract description 17
- 238000001378 electrochemiluminescence detection Methods 0.000 abstract description 8
- 230000000890 antigenic effect Effects 0.000 abstract description 6
- 238000012546 transfer Methods 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 238000003364 immunohistochemistry Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 38
- 238000011282 treatment Methods 0.000 description 32
- 201000011510 cancer Diseases 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 238000012216 screening Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000037029 cross reaction Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000011735 vitamin B7 Substances 0.000 description 6
- 240000008574 Capsicum frutescens Species 0.000 description 5
- 102000006601 Thymidine Kinase Human genes 0.000 description 5
- 108020004440 Thymidine kinase Proteins 0.000 description 5
- 229930003756 Vitamin B7 Natural products 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000000630 rising effect Effects 0.000 description 5
- 108010036901 thymidine kinase 1 Proteins 0.000 description 5
- 235000011912 vitamin B7 Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 235000013345 egg yolk Nutrition 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 201000010536 head and neck cancer Diseases 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 229920001206 natural gum Polymers 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000007413 biotinylation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 208000025866 malignant neoplasm of endocervix Diseases 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 238000007476 Maximum Likelihood Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000025915 regulation of apoptotic process Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000009871 tenuigenin Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- -1 amine ion Chemical class 0.000 description 1
- 238000003453 ammonium sulfate precipitation method Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000003037 histogenic effect Effects 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110353972 CN102432683B (zh) | 2011-10-28 | 2011-10-28 | 一种多表位tk1抗体的制备及其在肿瘤患者早期复发风险及预后评估中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110353972 CN102432683B (zh) | 2011-10-28 | 2011-10-28 | 一种多表位tk1抗体的制备及其在肿瘤患者早期复发风险及预后评估中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102432683A CN102432683A (zh) | 2012-05-02 |
CN102432683B true CN102432683B (zh) | 2013-10-30 |
Family
ID=45981067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110353972 Active CN102432683B (zh) | 2011-10-28 | 2011-10-28 | 一种多表位tk1抗体的制备及其在肿瘤患者早期复发风险及预后评估中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102432683B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102504027B (zh) * | 2011-10-28 | 2013-10-30 | 周际 | 一种多表位tk1抗体的制备及其在人群体检筛查中早期肿瘤检测和风险预警中的应用 |
CN106556592B (zh) * | 2015-09-24 | 2019-05-21 | 深圳市安群生物工程有限公司 | 定量检测人tk1的化学发光试剂盒及其制备方法 |
EP3497449A4 (en) * | 2016-08-10 | 2020-07-29 | Alertix Veterinary Diagnostics AB | DETERMINATION OF TK1 PROTEIN CONTENT OF NON-HUMAN MAMMALS |
CN110873711B (zh) * | 2018-09-04 | 2022-02-22 | 华瑞同康生物技术(深圳)有限公司 | 一种基于全自动化学发光分析仪的血清tk1检测试剂盒 |
CN110872354B (zh) * | 2018-09-04 | 2022-11-01 | 华瑞同康生物技术(深圳)有限公司 | 哺乳动物细胞重组抗人tk1的鸡源的单克隆抗体、单链抗体及其制备方法和应用 |
CN110878123B (zh) * | 2018-09-05 | 2022-08-23 | 华瑞同康生物技术(深圳)有限公司 | 一种抗tk1原核重组单链抗体及制备方法 |
CN112646039B (zh) * | 2021-01-06 | 2022-07-22 | 华瑞同康生物技术(深圳)有限公司 | Tk1抗体、试剂盒及其用途 |
CN112940131A (zh) * | 2021-02-04 | 2021-06-11 | 福建亿彤生物科技有限公司 | 一种针对人血清中tk1的兔单克隆抗体及应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1414017A (zh) * | 2002-09-13 | 2003-04-30 | 深圳市华瑞同康生物技术有限公司 | 抗细胞质胸苷激酶-IgY的制备及肿瘤诊断组合物 |
CN101186922A (zh) * | 2007-12-21 | 2008-05-28 | 丁克祥 | 一种基因免疫制备人类ⅰ型胸苷激酶单克隆抗体的新方法 |
-
2011
- 2011-10-28 CN CN 201110353972 patent/CN102432683B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1414017A (zh) * | 2002-09-13 | 2003-04-30 | 深圳市华瑞同康生物技术有限公司 | 抗细胞质胸苷激酶-IgY的制备及肿瘤诊断组合物 |
CN101186922A (zh) * | 2007-12-21 | 2008-05-28 | 丁克祥 | 一种基因免疫制备人类ⅰ型胸苷激酶单克隆抗体的新方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102432683A (zh) | 2012-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102432683B (zh) | 一种多表位tk1抗体的制备及其在肿瘤患者早期复发风险及预后评估中的应用 | |
CN102504027B (zh) | 一种多表位tk1抗体的制备及其在人群体检筛查中早期肿瘤检测和风险预警中的应用 | |
CN104374919B (zh) | 糖蛋白的测定方法、试剂及糖链标记物 | |
Granato et al. | Role of HE4, CA72. 4, and CA125 in monitoring ovarian cancer | |
US20090047689A1 (en) | Autoantigen biomarkers for early diagnosis of lung adenocarcinoma | |
CN102516390B (zh) | 一种多表位tk1抗体的制备及其在评估肿瘤患者治疗效果中的应用 | |
JP2007504463A (ja) | 卵巣癌用の診断マーカー | |
CN102687011B (zh) | 癌症生物标志物及其应用 | |
KR20140019833A (ko) | 유방암의 바이오마커 | |
US9562906B2 (en) | Methods for detection of gastric cancer | |
US20130116343A1 (en) | Salivary Protein Markers for Detection of Breast Cancer | |
WO2019010429A1 (en) | METHODS OF DIAGNOSING PANCREATIC CANCER | |
CN106489074A (zh) | 作为转移性乳腺癌的生物标志物的s100p和透明质酸 | |
CN109975549A (zh) | 肿瘤来源IgG在胰腺癌诊断或预后中的用途 | |
ES2641479T3 (es) | Sistemas y métodos para tratar, diagnosticar y predecir la respuesta a la terapia del cáncer de mama | |
CN107266567A (zh) | Lcrmp4单克隆抗体及其制备方法与应用 | |
KR20150129932A (ko) | 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 | |
CN110818797B (zh) | 一种抗人ca153蛋白的重组抗体 | |
CN110818796B (zh) | 一种抗人ca153蛋白的重组抗体 | |
CN116559462A (zh) | 用于肿瘤患者预后的生物标志物组及其用途 | |
CN100504393C (zh) | 蛋白masp的特异性结合试剂在制备诊断试剂中的用途 | |
EP3102600B1 (en) | Composition and method for detecting malignant neoplastic disease | |
US20160341733A1 (en) | Detection and treatment of cancer | |
EP3698138B1 (en) | Assay and kit for the diagnosis of ovarian carcinoma | |
CN114641690A (zh) | 用于确认、检测和评估前列腺癌进展的方法以及相关治疗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: LI JIN SMANIOTTO ANNA BAIS GIORGIO Effective date: 20140321 Owner name: SSTK BIO-TECH. (SHENZHEN) CO., LTD. Free format text: FORMER OWNER: ZHOU JI Effective date: 20140321 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140321 Address after: 518057, a biological incubator building 2-304A, B, Nanshan District hi tech, Guangdong, Shenzhen Patentee after: Tongkang Biotechnology (Shenzhen) Co., Ltd. Address before: 4, 518057, window garden, Nanshan District, Guangdong, Shenzhen 606 Patentee before: Zhou Ji Patentee before: Li Jin Patentee before: Sven. Skoog Patentee before: Alan He |
|
CP02 | Change in the address of a patent holder |
Address after: 518000 Guangzhou Longhua District Guanlan Street Xinlan Community Tourist Road 1301-76 Yinxing Zhijie Phase II Building A201A301 Patentee after: Tongkang Biotechnology (Shenzhen) Co., Ltd. Address before: 518057, a biological incubator building 2-304A, B, Nanshan District hi tech, Guangdong, Shenzhen Patentee before: Tongkang Biotechnology (Shenzhen) Co., Ltd. |
|
CP02 | Change in the address of a patent holder |